ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Discussion on the Treatment Strategy for Stage IIA1 Cervical Cancer (FIGO 2018)

Chen, Xiaolin; Liang, Wentong; Duan, Hui; Wu, Minling; Zhan, Xuemei; Dai, Encheng; Lv, Qiubo; Xie, Qinghuang; Liu, Ruilei; Xu, Yan; Bin, Xiaonong; Lang, Jinghe; Liu, Ping*; Chen, Chunlin*广州医学院; 南方医科大学; 中国医学科学院北京协和医院
Frontiers in Oncology2022-4-14DOI: 10.3389/fonc.2022.800049
2被引6阅读
引用收藏
分享

摘要

ObjectiveThis study aimed to explore the best treatment strategy for International Federation of Gynecology and Obstetrics (FIGO) 2018 stage IIA1 cervical cancer patients by comparing the survival outcomes of two treatment methods: abdominal radical hysterectomy (ARH) with standard postoperative therapy and radio-chemotherapy (R-CT). MethodsPatients with FIGO2018 stage IIA1 cervical cancer who underwent ARH or received R-CT were screened from the clinical diagnosis and treatment for cervical cancer in China (Four C) database. The recurrence cases between the two groups were analyzed. The 5-year overall survival (OS) and disease-free survival (DFS) of patients diagnosed with stage IIA1 cervical cancer in 47 hospitals in mainland China between 2004 and 2018 were compared by using propensity score matching (PSM). ResultsA total of 724 patients met the inclusion criteria. In the total study population, The R-CT group had higher recurrence (22.8% for the R-CT group and 11.2% for the ARH group, P<0.001) rates compared to the ARH group.The 5-year OS and DFS of the ARH group (n=658) were significantly higher than those of the R-CT group (n=66) (OS: 85.9% vs. 71.2%, P=0.009; DFS: 79.2%vs. 70.5%, P=0.027). R-CT was associated with worse 5-year OS (HR=3.19, 95% CI: 1.592-6.956, P=0.001) and DFS (HR=2.089, 95% CI: 1.194-3.656, P=0.01). After 1:2 PSM, the 5-year OS and DFS of the ARH group (n=126) were significantly higher than those of the R-CT group (n=64) (OS:88.9% vs. 70.1%, P=0.04; DFS:82.8% vs. 69.8%, P=0.019). R-CT was still associated with worse 5-year OS (HR=2.391, 95% CI: 1.051-5.633, P=0.046) and DFS (HR=2.6, 95% CI: 1.25-5.409, P=0.011). ConclusionOur study demonstrated that for stage FIGO2018 stage IIA1 cervical cancer patients, ARH offers better oncological outcomes than R-CT.

学科与关键词

关键词
cervical cancerstage IIA1overall survivaldisease-free survivaltreatment strategies
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2022-04-14
卷期
第 12 卷
页码
800049
DOI
10.3389/fonc.2022.800049
期刊等级
3区
成果收录
SCIE
资助标注
National Science and Technology Support Program of China [014BAI05B03]; National Natural Science Fund of Guangdong [2015A030311024]; Science and Technology Plan of Guangzhou [158100075]

作者

  • C

    Chen, Xiaolin (第一作者)

    southern med univ

  • L

    Liang, Wentong

    guizhou prov peoples hosp

查看全部 14 位作者收起作者
  • D

    Duan, Hui

    southern med univ

  • W

    Wu, Minling

    southern med univ

  • Z

    Zhan, Xuemei

  • D

    Dai, Encheng

    linyi peoples hosp

  • L

    Lv, Qiubo

    beijing hosp

  • X

    Xie, Qinghuang

  • L

    Liu, Ruilei

    linyi peoples hosp

  • X

    Xu, Yan

    panyu cent hosp

  • B

    Bin, Xiaonong

    guangzhou med univ

  • L

    Lang, Jinghe

    peking union med coll · peking union med coll hosp

  • L

    Liu, Ping (通讯)

    southern med univ

  • C

    Chen, Chunlin (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417